Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Moshe Talpaz, John Mascarenhas, Ronald Hoffman Abstract: P 699 Session topic: 16. Myeloproliferative neoplasms – Clinical ...
RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Martin Greisshammer, Guray Saydam, Francesca Palandri, et. al. Abstract: S 784 Session topic: 16. Myeloproliferative neoplasms –...
Myeloproliferatívna neoplázia: novinky z kongresu
15 októbra, 2020 7:26 pm Leave your thoughtsV poradí 22. kongres Európskej hematologickej asociácie bol mimoriadne úspešný. Viac ako 10-tisíc delegátov, rekordných 2 500 prihlásených abstraktov, 60 prednášok v rámci...
IS THE SPLENECTOMY OUTCOME PREDICTABLE IN PATIENTS WITH ITP?
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Mirjana Mitrovic, Slavko Matic, Jelena Bodrozic, et. al. Abstract: E1448 Session topic: 32. Platelets disorders Background:...
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): James Bussel, Michael Tarantino, Victor Blanchette, et. al. Abstract: P 727 Session topic: 32. Platelets disorders ...
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): J Bussel, J Mayer, L Cervinek, K Chojnowski, et. al. Abstract: S 435 Session topic: 32. Platelets...
REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY
15 októbra, 2020 7:25 pm Leave your thoughtsAuthor(s): Emilio Ojeda Gutiérrez, Abdulgabar Salama, Jean-François Viallard, et. al. Abstract: P 720 Session topic: 32. Platelets disorders...
Optimalizácia liečby imúnnej trombocytopénie a nové stratégie liečby trombocytopénie pri aplastickej anémii a myelodysplastickom syndróme
15 októbra, 2020 7:25 pm Leave your thoughtsNa tohtoročnom kongrese EHA odzneli viaceré prednášky na tému imúnnej trombocytopénie (ITP), jej patofyziológie, nových možností a optimalizácie jej liečby. ITP je získané...
PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS
15 októbra, 2020 7:25 pm Leave your thoughtsAuthor(s): Jakob Werner Hansen, Maj Westman, Andreas Due Orskov, et. al. Abstract: S 486 Session topic: 10. Myelodysplastic...
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
15 októbra, 2020 7:25 pm Leave your thoughtsAuthor(s): Aaron T. Gerds, Bart L. Scott, Peter Greenberg, et. al. Abstract: P 662 Session topic: 10. Myelodysplastic...